The estimated Net Worth of Marc Grasso is at least $5.07 Million dollars as of 3 September 2024. Marc Grasso owns over 7,297 units of Kura Oncology Inc stock worth over $2,599,111 and over the last 5 years he sold KURA stock worth over $357,579. In addition, he makes $2,112,280 as Chief Financial Officer and Chief Business Officer at Kura Oncology Inc.
Marc has made over 11 trades of the Kura Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 7,297 units of KURA stock worth $35,609 on 3 September 2024.
The largest trade he's ever made was exercising 10,000 units of Kura Oncology Inc stock on 14 September 2020 worth over $290,000. On average, Marc trades about 3,998 units every 88 days since 2020. As of 3 September 2024 he still owns at least 130,740 units of Kura Oncology Inc stock.
You can see the complete history of Marc Grasso stock trades at the bottom of the page.
Dr. Marc Grasso M.D. serves as Chief Financial Officer and Chief Business Officer of the Company. He has served as our Chief Financial Officer and Chief Business Officer since August 2018. Prior to joining us, he served as Managing Director at Stifel Financial Corp., an investment bank and financial services company, from March 2013 to July 2018, where he was responsible for building and managing Stifel’s west coast life sciences and biotechnology investment banking business. From June 2010 to February 2013, Dr. Grasso was Managing Director of Investment Banking in the Global Healthcare Group at UBS Group AG, focused on the biotechnology sector, and from May 2008 to June 2010 he was Managing Director of Investment Banking at Leerink Swann LLC (“Leerink”), a specialist investment bank focused on the healthcare sector, where he was instrumental in the west coast expansion of their franchise. Dr. Grasso joined Leerink from Morgan Stanley, where he served as an Executive Director of Investment Banking in the Global Healthcare Group. Prior to joining Morgan Stanley, he was Vice President of Investment Banking in the Global Healthcare Group of Credit Suisse First Boston. He began his career in investment banking at Deutsche Banc Alex. Brown Inc. Dr. Grasso received his M.D. from The Johns Hopkins University School of Medicine, where he also performed research in molecular oncology. He obtained an A.B. in molecular biology with honors from Princeton University.
As the Chief Financial Officer and Chief Business Officer of Kura Oncology Inc, the total compensation of Marc Grasso at Kura Oncology Inc is $2,112,280. There are 2 executives at Kura Oncology Inc getting paid more, with Kathleen Ford having the highest compensation of $3,485,030.
Marc Grasso is 47, he's been the Chief Financial Officer and Chief Business Officer of Kura Oncology Inc since 2019. There are 18 older and 2 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.
Marc's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Kura Oncology Inc have traded over $16,903,587 worth of Kura Oncology Inc stock and bought 50,000 units worth $575,000 . The most active insiders traders include Faheem Hasnain, Troy Edward Wilson, and Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of $626,260. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth $57,922.
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
Kura Oncology Inc executives and other stock owners filed with the SEC include: